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At present, there is no consensus as to how Ras isPamela Das,² Michael D. Waterfield,²³
able to control Rac proteins and actin polymerization.Anne Ridley,² and Julian Downward*
Several proteins have been identified that interact di-*Imperial Cancer Research Fund
rectly with active, GTP-bound Ras, but not with inactive,London WC2A 3PX
GDP-bound Ras: these are all potential effectors, orUnited Kingdom
downstream targets, of Ras. The best characterized of²Ludwig Institute for Cancer Research
these is the Raf family of cytoplasmic serine/threonineLondon W1P 8BT
kinases (Marshall, 1996). Ras interaction with Raf leadsUnited Kingdom
to activation of the MAP kinase pathway with subse-³Department of Biochemistry
quent regulation of transcription factors; this pathwayUniversity College London
has been shown to be essential for fibroblast prolifera-London WC1E 6BT
tion, but there is evidence that it is not directly involvedUnited Kingdom
in short-term control of the cytoskeleton (Joneson et
al., 1996).
A number of reports support the existence of other
Summary effector pathways operating downstream of Ras in addi-
tion to the Raf/MAP kinase pathway (White et al., 1995;
The pathways by which mammalian Ras proteins in- Joneson et al., 1996). Other putative mammalian Ras
duce cortical actin rearrangement and cause cellular effectors include the family of Ras GTPase-activating
transformation are investigated using partial loss of proteins, among them p120GAP, neurofibromin, and Gap1
function mutants of Ras and activated and inhibitory (Marshall, 1996), which are negative regulators of Ras
forms of various postulated target enzymes for Ras. but could possibly influence Rho family proteins through
Efficient transformation by Ras requires activation of the p120GAP-associated protein p190, a Rho family GAP.
other direct effectors in addition to the MAP kinase Another family of putative Ras effectors, Ral.GDS, and
kinase kinase Raf and is inhibited by inactivation of the two related proteins activate the Ras family member Ral
PI 3-kinase pathway. Actin rearrangement correlates in response to activation of Ras (Urano et al., 1996). At
with the ability of Ras mutants to activate PI 3-kinase. present, the function of Ral is unknown, although a role
Inhibition of PI 3-kinase activity blocks Ras induction in the regulation of phospholipase D has been sug-
of membrane ruffling, while activated PI 3-kinase is gested. A protein that interacts with activated Ral has
sufficient to induce membrane ruffling, acting through recently been identified (Cantor et al., 1995) that con-
Rac. The ability of activated Ras to stimulate PI tains a Rac GAP domain, establishing another effector
pathway by which Ras might perhaps be able to influ-3-kinase in addition to Raf is therefore important in
ence the activity of Rho family proteins.Ras transformation of mammalian cells and essential
In fission yeast, Ras has been shown to directly regu-in Ras-induced cytoskeletal reorganization.
late two effectors. One is a MAP kinase kinase kinase,
Byr2, the other is Scd1, a guanine nucleotide exchangeIntroduction
factor for the Rho family protein Cdc42, which is involved
in regulation of cell morphology (Chang et al., 1994).In addition to their well characterized roles as inducers
There is therefore a precedent for Ras directly control-of cellular proliferation, Ras proteins are known to have
ling a Rho family exchange factor, although no suchprofound and rapid effects on the actin cytoskeleton;
connection has yet emerged in mammalian systems;
both pathways are likely to be important in establishing
yeast does not always accurately mirror mammalian
and maintaining the transformed phenotype. When
pathways, with adenylyl cyclase being a Ras effector in
microinjected into fibroblasts, activated mutant Ras S. cerevisiae, but not in other species.
protein induces membrane ruffling due to cortical actin One other mammalian Ras effector has been de-
rearrangement within a few minutes (Bar Sagi and Fera- scribed that might be capable of mediating Ras control
misco, 1986). Membrane ruffling or lamellipodia forma- of the cytoskeleton. Phosphoinositide 3-OH kinase (PI
tion is also induced by a number of growth factors and 3-kinase) interacts with Ras.GTP but not with Ras.GDP
by microinjection of activated mutant Rac protein, a and is activated both in vitro and in vivo as a result of
member of the Rho subfamily of Ras-related small this interaction (Kodaki et al., 1994; Rodriguez-Viciana
GTPases (Ridley et al., 1992). Since dominant-negative et al., 1994, 1996). PI 3-kinase has been implicated in
mutant Rac blocks induction of ruffling by Ras and by the regulation of the actin cytoskeleton by growth fac-
growth factors, it is likely that Rac functions downstream tors such as PDGF and insulin (Kotani et al., 1994; Wenn-
of Ras and growth factor receptors in the pathway lead- stroÈ m et al., 1994; Nobes et al., 1995).
ing to actin rearrangement. In Swiss 3T3 cells, Ras mi- Many mutations in the effector region of Ras, residues
croinjection also leads to actin stress fiber formation 32±40, are known to inhibit the biological function of Ras
through a Rho-mediated pathway that lies downstream and to block the interaction of Ras with target proteins.
of Rac (Ridley and Hall, 1992). These observations pro- Recently, it has become clear that relatively subtle muta-
tions in this region might lead to partial loss of functionvide compelling, though indirect, evidence that Ras is
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Figure 1. In Vitro Binding of Ras Mutants to
Effectors
(A) Mutant Ras proteins were loaded with
GTP (T) or GDP (D) and bound to GST-fusion
proteins of the effectors Ral.GDS (residues
1±97), c-Raf-1 (residues 1±259), and PI
3-kinase (full-length p110). Bound Ras was
visualized by immunoblotting with mono-
clonal antibody Y13-259. In the control lane
(cont), GST was substituted for effector fu-
sion protein. All mutants were in a V12 back-
ground.
(B) Ras mutant interaction with effectors was
measured by scintillation proximity assay.
GST-fusion proteins spanning the Ras-bind-
ing site in Ral.GDS and Raf were used. The
means and standard errors of triplicate
assays are shown.
mutants in which interaction with some effectors is et al., 1993; Spaargaren and Bischoff, 1994). It is appar-
ent that in most cases, Ras mutants show similar ability,maintained but with others is lost (Joneson et al., 1996;
White et al., 1995) (see Discussion). In this paper, we or lack of ability, to bind to these three effectors. A
number, however, are capable of preferentially bindingestablish which mammalian effectors interact with the
Ras partial loss of function mutants C40, G37, S35, and to one effector while failing to bind to the other two. In
particular, E38 and S35 are able to bind to Raf-1 butE38. We use these mutants, plus activated versions of
Ras effector pathways including Raf and phosphoinosi- not significantly to Ral.GDS or p110a, while G37 will
bind to Ral.GDS but not to Raf-1 or p110a, and C40 willtide 3-kinase (PI 3-kinase), to establish that at least two
of these pathways need to be activated for efficient bind to p110a but not to Raf-1 or Ral.GDS. Each of the
Ras mutants G37, E38, and C40 fail to show stimulationtransformation of murine fibroblasts. Ras transformation
is strongly inhibited by blocking PI 3-kinase activation. of GTPase activity in response to the GTPase-activating
proteins p120GAP and neurofibromin, while S35 showsThe mutants are also used to investigate the means by
which Ras controls the actin cytoskeleton in mammalian marginal sensitivity to p120GAP (data not shown). The use
of only the Ras-binding site of Raf and Ral.GDS in thesecells. PI 3-kinase is shown to be the effector by which
Ras induces membrane ruffling, since Ras-induced ruf- binding assays may have some limitations, particularly
if additional sites of interaction with Ras exist: this ap-fling is blocked by inhibition of PI 3-kinase function, and
PI 3-kinase activity is demonstrated to be sufficient to proach was used because of difficulties in obtaining
active forms of the full-length proteins. In the case ofcause membrane ruffling, in a manner involving Rac and
a target of calphostin C. Activation of Raf or Ral.GDS p110a, both full-length protein and the Ras-binding site
alone (Rodriguez-Viciana et al., 1996) have been usedis not sufficient to cause membrane ruffling.
to study Ras interactions with broadly similar results.
The ability of these four Ras effector mutants, plusResults
activated V12 Ras, to interact with the various Ras-
binding proteins was investigated in more detail. A scin-In Vitro Interaction of Mutant Ras
Proteins with Effectors tillation proximity assay (Skinner et al., 1994) was used
to estimate the relative binding affinities of these RasIn order to gain further insight into the relative impor-
tance of the various different effectors of Ras, we have mutants for Raf-1 and Ral.GDS. As shown in Figure 1B,
V12 Ras interacted strongly with Raf-1 in this assay: thescreened a large array of Ras mutants for their ability
to interact in vitro with the proven and suspected ef- affinity of this interaction has been reported to be about
40 nM. No interaction could be seen with G37 and C40.fectors c-Raf-1, Ral.GDS, and PI 3-kinase p110a (Figure
1A). The PI 3-kinase used was full-length p85/GST- E38 interacted with Raf-1 with about a 5-fold-reduced
affinity relative to V12, while S35 bound somewhat morep110a purified from a baculovirus expression system
(Rodriguez-Viciana et al., 1996), while the Raf-1 and weakly. In the case of Ral.GDS, E38 and C40 showed
no detectable binding, while the affinity of G37 bindingRal.GDS used were bacterially expressed GST-fusion
proteins containing the Ras-binding site alone (Warne to Ral.GDS was reduced by about 3-fold relative to V12,
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Figure 2. Effects of Ras Mutants on Effector Activity in COS Cells
Ras mutants (in a V12 background) were transfected into COS-7 cells. For PI 3-kinase, Ras mutants were transfected along with wild-type
p110a or alone as indicated. p110* is the activated PI 3-kinase mutant K227E p110a. PIP3 levels were measured in whole cells 48 hr after
transfection. Raf activity was measured by cotransfecting Ras mutants with epitope-tagged wild-type c-Raf-1. After 48 hr, the Raf was
immunoprecipitated and assayed in a coupled assay for its ability to activate MEK. The means and standard errors of duplicate assays are
shown. Representative of at least three experiments.
while that of S35 was reduced by more than 10-fold. also of activated effectors themselves, to transform NIH
3T3 cells was studied by focus formation assays. AsThe scintillation proximity assay proved to be unsuitable
for studying the interaction of Ras with either PI 3-kinase shown in Figure 3A, none of the three Ras effector mu-
tants G37, S35, and C40 in a V12 background were ableor neurofibromin, possibly reflecting the relatively low
affinities of these interactions, both around 200 nM. Pre- to induce transformation by themselves. However, as
has been reported for G37 and S35 (White et al., 1995),vious use of this assay to study Ras interaction with
neurofibromin relied on the use of L61 Ras, which has each pairwise combination of G37, S35, and C40 was
able to induce transformation, albeit considerably lessa higher affinity for GAPs (Skinner et al., 1994).
strongly than V12 Ras itself (in Figure 3, 20 ng of V12 Ras
plasmid was used, but1.5 mg of every other construct). ItActivation of Effectors by Ras Mutants
in Intact Cells is therefore likely that each of the three mutants is capa-
ble of activating a separate effector pathway, each ofThe ability of the Ras mutants described above to acti-
vate effector pathways was investigated in intact cells. which can contribute to transformation. In these assays,
we found that E38 behaved very similarly to S35 (dataPI 3-kinase activation was investigated by transfecting
Ras effector mutants, in a V12-activated background, not shown).
The ability of downstream effectors of Ras to trans-into COS cells along with the p110a catalytic subunit of
PI 3-kinase. As reported previously (Rodriguez-Viciana form cells was also determined (Figure 3A). Raf activated
by deletion of the amino-terminal regulatory region is aet al., 1994), V12 Ras synergizes strongly with PI
3-kinase expression to give greatly elevated levels of the weaker oncogene by itself than Ras, but it synergizes
strongly with activated mutants of PI 3-kinase, Rac andlipid product phosphatidylinositol (3,4,5) trisphosphate
(PIP3). As shown in Figure 2, S35, G37, and E38 Ras all Rho, none of which are transforming by themselves.
Interestingly, PI 3-kinase will not synergize with Rac,failed to elevate PIP3 levels in this assay, while C40
stimulated to about 35% of the level achieved with V12 suggesting that they function on the same pathway, but
PI 3-kinase will synergize with Rho. Rac and Rho alsoRas. The in vivo activity of these mutants thus mirrored
their in vitro binding affinity for PI 3-kinase. synergize in the transformation assay, suggesting that
they are not acting in the same pathway. We were unableRaf activation by Ras mutants was also determined
in COS cells by cotransfection of Ras mutants (in a V12 to see any effects of activated L72 Ral in these assays
(data not shown). Cooperation of Ras effector mutantsbackground) with tagged Raf (Leevers and Marshall,
1992). V12 Ras strongly stimulates Raf, while G37 and with effectors themselves was also tested (Figure 3B).
S35 Ras synergized with PI 3-kinase, Rac, and Rho, butC40 are entirely inactive. S35 and E38 Ras both activate
Raf, but about 3- to 4-fold less strongly than V12. Again, not with Raf. C40 Ras synergized with Raf and Rho, but
not with Rac or PI 3-kinase. G37 Ras synergized withthe ability of Ras mutants to activate Raf in this cell-
based assay correlates well with their in vitro binding Raf, Rac, and PI 3-kinase, and more weakly with Rho.
From these data, it can be concluded that at least theto Raf.
Raf/MAP kinase pathway (activated by S35) and the PI
3-kinase/Rac pathway (activated by C40) act down-Contribution of Ras Effector Pathways
to Transformation stream of Ras to induce transformation synergistically.
The role of Ral.GDS in transformation is less clear: weIn order to assess the importance of the various Ras
effector pathways in fibroblast transformation, the abil- were unable to see any effects of activated Ral, but
synergy between Ral and Raf has been reported recentlyity of the Ras effector mutants described above, and
Cell
460
Figure 4. Inhibition of Ras Transformation of NIH 3T3 Cells by Domi-
nant-Negative PI 3-Kinase
V12 Ras or v-Src was transfected into NIH 3T3 cells along with the
indicated constructs, including p85-derived dominant-negative PI
3-kinase constructs, dominant-negative Rac and MEK, and the SH2
and SH3 domains of p120GAP. Focus formation was quantitated after
two weeks.
therefore used the well characterized dominant-nega-
tive mutant of the PI 3-kinase regulatory subunit, p85,
which lacks the binding site for the catalytic subunit,
p110 (Dhand et al., 1994). This dominant-negative PI
3-kinase (p85 DiSH2-N, widely referred to elsewhere as
Dp85) strongly inhibits transformation by V12 Ras, but
not by v-Src, as assessed by focus formation (Figure
4). The expression of this mutant, or any other form of
p85, does not reduce the efficiency of formation and
growth of drug-resistant colonies of these cells, either
Figure 3. Transformation of NIH 3T3 by Ras Mutants and Effectors in the presence or absence of activated Ras (data not
(A) Ras mutants (in a V12 background) were transfected into NIH shown): the reduction in transformed foci is therefore
3T3 cells either alone or in combinations. Focus formation assays
not due to a general toxicity resulting from inhibition ofwere performed over two weeks. The following Ras effectors and
PI 3-kinase, but appears to be a specific effect on theother signaling proteins were assayed for transformation alone and
ability of Ras, but not Src, to transform these cells. Byin combination: D1±295 Raf, K227E p110a, V12 Rac, and V14 Rho.
Assays were performed using 20 ng of V12 Ras plasmid and 1.5 mg contrast, the strong inhibition of transformation by both
of every other construct. Ras and Src seen on coexpression of dominant-negative
(B) Ras effector mutants in a V12 background were assayed for N17 Rac is accompanied by a very marked reduction,
transformation in combination with D1±295 Raf, V12 Rac, V14 Rho,
greater than 80%, in drug-resistant colony formation,and K227E p110a. Assays were performed using 20 ng of V12 Ras
suggesting that expression of N17 Rac is inhibitory forplasmid and 1.5 mg of every other construct.
normal as well as transformed cell growth (data not
shown). As would be expected, dominant-negative
MEK, an inhibitor of the Raf/MAP kinase pathway, signif-(Urano et al., 1996). It is possible that Ral.GDS activates
other targets in addition to Ral, and also that G37 might icantly blocks Ras transformation, showing that the Raf
pathway is also critical for Ras transformation.interact with other unknown effectors in addition to
Ral.GDS. In addition to p85 DiSH2-N, the inhibitory ability of
full-length p85 and also mutants lacking the Bcr-related
Rho GAP±like region (p85 Dbcr) or a region in the inter-Ras Transformation Requires
PI 3-Kinase Function SH2 domain C-terminal to the p110 interaction site (p85
DiSH2-C) were also tested. All three of these inhibitedA direct way of testing the hypothesis that the PI
3-kinase pathway is important in the transformation of Ras, but not Src, transformation. Overexpression of full-
length p85 inhibits PI 3-kinase signaling, albeit lesscells by Ras is to determine the effect of inhibition of
this enzyme on V12 Ras transformation of NIH 3T3 cells. strongly than p85 with the p110 interaction site deleted
(Kodaki et al., 1994 and our unpublished data), probablyThe long-term nature of transformation assays means
that the use of chemical inhibitors of PI 3-kinase, particu- by titering out stimulatory molecules that bind to the
regulatory subunit in much the same way in which p85larly unstable ones such as wortmannin, is not ideal. We
PI 3-Kinase and Ras Signaling
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to inhibit filopodia formation induced by extracellularTable 1. Inhibition of Growth in Soft Agar of Ras-Transformed
NIH 3T3 Cell Lines by Expression of p85 Constructs stimuli in another system (A. R., unpublished data).
To investigate whether PI 3-kinase activity was re-Vector V12 Ras Clone 1 V12 Ras Clone 2 v-Src
sponsible for the Ras-induced membrane ruffling, PAE
Control 272 6 37 218 6 45 326 6 82 cells microinjected with V12 Ras, V12 C40 Ras, activated
p85a 42 6 5 48 6 12 291 6 68
PI 3-kinase, or V12 Rac were treated with the PIp85b 5 6 1 6 6 2 278 6 89
3-kinase inhibitor LY294002. This inhibitor completelyDp85a 22 6 3 28 6 7 310 6 45
blocked the ability of V12 C40 Ras and activated PI
The numbers of colonies visible by the naked eye are listed. Clone 3-kinase to induce membrane ruffling (Figure 6A). In
1 expresses low and Clone 2, high levels of V12 Ras. Representative
addition, this drug blocked PDGF-induced ruffling inof two separate experiments.
these cells (data not shown and WennstroÈ m et al., 1994).
However, LY294002 had absolutely no effect on the acti-
vation of the MAP kinase ERK2 in response to PDGF or
DiSH2-N does. Presumably, some productive com- phorbol ester in these cells (data not shown). Ruffling
plexes with p110 will form, but at high levels of p85 induced by V12 Ras was not fully blocked by LY294002,
expression, these will be effectively removed from up- although some clear diminution of the extent of ruffling
stream signaling by competition from free p85. The Bcr- was reproducibly noticed. V12 Rac±induced ruffling was
related region of p85 has been reported to interact with unaffected by LY294002. For all of these experiments,
the Rho family proteins Cdc42 and Rac (Zheng et al., similar effects to LY294002 were also seen with wort-
1994); the fact that p85 Dbcr has identical activity to mannin, an unrelated inhibitor of PI 3-kinase activity
p85 and p85 DiSH2-N in this assay suggests that direct (data not shown). It therefore appears that PI 3-kinase,
interaction of p85 with Rac or Cdc42 is not likely to be and not Raf or Ral.GDS, is one of the Ras effectors
a critical part of the mechanism of Ras transformation. involved in the induction of cortical actin rearrangement,
The expression of the SH2 and SH3 domains of p120GAP membrane ruffling, and lamellipodia formation. How-
does not inhibit Ras transformation, suggesting that the ever, it is possible that another ruffling pathway also
inhibitory effect of p85 is not nonspecific due to overex- exists that is activated by V12 Ras but not V12 C40 Ras
pression of any SH2 and SH3 domains. and is insensitive to chemical inhibitors of PI 3-kinase.
To confirm the inhibitory effect of blocking PI 3-kinase To further investigate this PI 3-kinase inhibitor±
function on the ability of oncogenic Ras to transform resistant pathway linking Ras to Rac and membrane
cells, NIH 3T3 cell lines stably transformed by V12 Ras ruffling, the effects of a number of other inhibitors on
were infected with retroviruses expressing dominant- Ras-induced membrane ruffling were studied. The p85-
negative p85 constructs. Drug-resistant pools of in- derived dominant-negative PI 3-kinase constructs were
fected cells were assayed for their ability to grow in coexpressed in PAE cells with activated Ras or Rac.
suspension in softagar. As shown in Table 1, expression As shown in Figure 6B, expression of p85 totally and
of either full-length p85a or p85b, or Dp85a, all substan- reproducibly blocked V12 Ras±induced membrane ruf-
tially inhibited colony formation of Ras-transformed fling. In addition, p85 DiSH2-N, p85 Dbcr, and p85
cells in soft agar. Expression of these constructs had DiSH2-C all completely inhibited V12 Ras±induced ruf-
no significant effects on v-Src-induced anchorage-inde- fling. These constructs also block PDGF-induced ruf-
pendent cell growth. fling (WennstroÈ m et al., 1994 and data not shown). The
p120GAP SH2 and SH3 construct was without effect.
Involvement of Ras Effector Pathways The effect of these p85-based dominant-negative PI
in Cytoskeletal Reorganization 3-kinase constructs appeared to be specific for Ras-
Microinjection of activated Ras protein or cDNA into and growth factor±induced ruffling, since they had abso-
porcine aortic endothelial (PAE) cells induces rapidcorti- lutely no effect on ruffling induced by V12 Rac (Figure
cal actin rearrangement and membrane ruffling. Expres- 6B and data not shown). These data indicate that the
sion vectors for the various Ras effector mutants, and mechanism by which Ras controls the actin cytoskele-
the activated effectors themselves, were injected into ton through Rac is entirely dependent on normal PI
PAE cells and the cells subsequently stained with phal- 3-kinase function acting upstream of Rac. The inability
loidin-rhodamine to visualize F actin. As shown in Figure of chemical inhibitors of PI 3-kinase to inhibit fully Ras-
5A, while activated V12 Ras gave strong membrane ruf- induced actin rearrangement may suggest that drug-
fling, S35 and G37 Ras in V12 backgrounds failed to resistant forms of PI 3-kinase couple to Ras.
induce actin rearrangements. V12 C40 Ras induced As shown in Figure 6C, the protein kinase C inhibitor
membrane ruffling, although more weakly than V12 Ras. calphostin C was a very good inhibitor of ruffling induced
It therefore appears likely that PI 3-kinase is a down- both by Ras and by PDGF in PAE cells. Calphostin C was
stream effector involved in Ras-induced ruffling. An acti- also able to fully inhibit activated PI 3-kinase±induced
vated mutant of PI 3-kinase was sufficient to cause ruffling. However, another protein kinase C inhibitor, the
membrane ruffling. Activated Rac gave strong ruffling, bisindoylmaleimide GF 109203X, was not effective. The
while activated Raf-CAAX and L72 Ral did not. PI inhibitor GF 109203X was used under conditions where
3-kinase-induced ruffling was inhibited by coexpression it inhibited phorbol ester activation of ERK2 (data not
of dominant-negative N17 Rac, but not dominant-nega- shown). Since calphostin C acts on diacyl glycerol±
tive N17 Ras or N17 Cdc42, while V12 Ras±induced binding zinc fingers, while bisindoylmaleimide acts on
ruffling was sensitive to dominant-negative Rac but not the kinase domain, it is possible that a diacyl glycerol±
binding protein other than a protein kinase C familyCdc42 (Figure 5B). This N17 Cdc42 construct was able
Cell
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Figure 5. Effect of Ras Mutants and Effectors on Actin Rearrangement in Porcine Aortic Endothelial Cells
(A) PAE cells were microinjected with the indicated plasmids (p110* is the activated PI 3-kinase K227E p110a) and actin visualized after 5 hr
by immunofluorescence using TRITC-phalloidin.
(B) Cells were microinjected with V12 Ras protein or K227E p110a plasmid, along with dominant-negative Ras, Rac, or Cdc42 protein or
plasmid, respectively.
member is important in the control of membrane ruffling: LY294002 fails to do so, COS cells were transfected
with V12 Ras in the presence or absence of p85 orpossible candidates include the Rho family exchange
factors Vav, Vav2, FGD1, and Lfc. Calphostin C was Dp85. The cells were then metabolically labeled with
32P-orthophosphate, and PIP3 levels were determined.unable to inhibit ruffling induced by activated Rac, plac-
ing the target for this drug downstream of Ras and PI As shown in Figure 7B, both p85 and Dp85 were able
toalmost completely reverse V12 Ras±induced elevation3-kinase and upstream of Rac.
of PI 3-kinase lipid products. These constructs did not
influence Ras expression levels (data not shown).Effect of LY294002 on PDGF- and Ras-Induced
Cellular PIP3 Levels
The data in Figure 6B raises the possibility that Ras may Discussion
be capable of affecting the activity of PI 3-kinases that
are not fully sensitive to chemical inhibitors such as The various partial loss of function mutants of Ras used
in this paper help to define the effector pathways actingLY294002 and wortmannin.To furtherexplore this possi-
bility, the effect of LY294002 on the levels of PI 3-kinase± downstream of Ras. It is clear that Ras can trigger multi-
ple signaling pathways in addition to the well character-produced lipids was investigated in NIH 3T3 cells (Figure
7A). PDGF-induced PIP3 elevation is entirely reversed ized Raf/MAP kinase cascade (White et al., 1995; Jone-
son et al., 1996; Marshall, 1996). We describe here theby treatment of cells with 20 mM LY294002, a dosage
that should entirely inhibit the activity of p110a (Vlahos ability of four different effector site mutants of Ras to
stimulate known effectors: C40 Ras interacts with PIet al., 1994). When V12 Ras was expressed in these
cells, the levels of PIP3 were constitutively elevated to 3-kinase, G37 Ras interacts with Ral.GDS, and S35 and
E38 Ras interact with Raf. None of these mutants inter-about half the peak level achieved with PDGF. This ele-
vation of PIP3 was, however, substantially resistant to act productively with p120GAP or neurofibromin. The abil-
ity of these mutants to interact with other potential mam-the effects of the drug; even extended treatment with
very high concentrations of LY294002 left about half this malian effectors of Ras is not known. S35 Ras has
previously been reported to interact selectively with Raf,level of PIP3. It is therefore likely that Ras couples to
forms of PI 3-kinase that are resistant to this drug, and but not with the unrelated MAP kinase kinase kinase,
Byr2, from Schizosaccharomyces pombe, while G37also activates conventional drug-sensitive isoforms.
To confirm that expression of the regulatory p85 sub- Ras interacts with Byr2 but not with Raf (White et al.,
1995): together, the two synergize strongly in transfor-unit of PI 3-kinase can block the ability of V12 Ras to
induce elevated levels of PIP3 in intact cells, even though mation of NIH 3T3 cells, as also shown here. The mutant
PI 3-Kinase and Ras Signaling
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Figure 6. Effect of Inhibitors on Ras-Induced Actin Rearrangement in Porcine Aortic Endothelial Cells
(A) PAE cells were microinjected with plasmids encoding activated Ras, PI 3-kinase, Rac, or V12 C40 Ras. Four hours after nuclear injection
of the constructs, LY294002 (LY) was added to the cells for another 90 min.
(B) p85-based dominant-negative PI 3-kinase constructs were microinjected along with V12 Ras or V12 Rac constructs. Actin was visualized
after 5 hr.
(C) Cells were injected with either V12 Ras or V12 Rac protein, or activated PI 3-kinase plasmid, or were treated with PDGF. Cells were
preincubated for 1 hr with 250 nM Calphostin C (CAL.) or 10 mM Bisindoylmaleimide 1/GF 109203X (BIM.) before injection of the V12 Ras or
V12 Rac proteins. The cells were then incubated for a further 60 and 30 min, respectively, before fixing. Where indicated, cells were stimulated
with 25 ng/ml PDGF for 4 min. For PI 3-kinase, cells were microinjected with the plasmid 5 hr before treatment with the inhibitors for 1 hr.
C40 has been reported to be unable to activate Raf, but Ral.GDS, and activated PI 3-kinase synergizes with Rho
and Raf, but not with Rac. We were unable to find effectsis able to induce membrane ruffling by an unknown
mechanism, while S35 fails to cause membrane ruffling of activated Ral on transformation: Ral.GDS may acti-
vate other targets in addition to Ral, or Ral.GDS maybut activates Raf (Joneson et al., 1996). Very recently,
it has been demonstrated that Ras can use unidentified not be the only effector binding to G37 Ras.
It appears that at least two effector pathways needpathways other than the Raf/MAP kinase pathway to
cause transformation of murine fibroblasts (Khosravi- to be activated by Ras for transformation to result. These
pathways can be Raf plus PI 3-kinase, or Raf or PIFar et al., 1996). It has also been shown that the V12
G37 mutant Ras is capable of interacting with Ral.GDS 3-kinase plus Ral.GDS, or another effector capable of
binding to G37 Ras. Even so, the synergistic transforma-(White et al., 1996).
Since Ras mutants that activate only Raf, such as E38 tion seen with two different Ras mutants or effectors in
Figure 3 falls well short of the efficiency of transforma-and S35, are very poorly transforming, it would appear
that activation of endogenous Raf protein alone is not tion seen with V12 Ras alone. This may reflect the fact
that the partial loss of function effector mutants of Rassufficient to transform murine fibroblasts, even though
overexpression of strongly activated Raf is transforming are significantly compromised in their ability to activate
even the effectors with which they still interact (seeby itself, possibly through a mechanism involving secre-
tion of autocrine growth factors (McCarthy et al., 1995). Figures 1B and 2). It may also be the case that more
than two effector pathways need to be activated forThe Raf mutant used in this study, which has had its
amino terminal regulatory domain deleted, is relatively truly high efficiency transformation. However, the fact
that dominant-negative forms of PI 3-kinase based onweakly activated, as it is not membrane localized. Rea-
sonable transformation is achieved by the Ras mutants the p85 regulatory subunit are able to inhibit V12 Ras
transformation very significantly indicates that this path-that activate only Raf in synergy either with Ras mutants
that activate Ral.GDS or PI 3-kinase or with activated way is one of those normally used by Ras oncogenes
to establish the transformed cell phenotype. Transfor-PI 3-kinase, Rac, or Rho. Similarly, the Ras mutant that
activates only PI 3-kinase synergizes with those activat- mation by v-Src appears to be much less sensitive to
inhibition of PI 3-kinase signaling: this may reflect theing other pathways, including the one that activates only
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acts upstream of Rho (Ridley et al., 1992; Ridley and
Hall, 1992). This apparent inconsistency may reflect dif-
ferences in cell types or, perhapsmore likely, differences
in the nature of the biological assay: it is possible that
distinct pools of Rho and Rac GTPases exist, with those
proteins involved in actin rearrangement being differ-
ently regulated from those involved in, for example, tran-
scriptional regulation. Transformation is likely to reflect
all aspects of Rac and Rho signaling, not just cytoskele-
tal effects.
The definition of a set of effector mutants of Ras that
each engage only one effector pathway allows one to
demonstrate that multiple pathways are required for effi-
cient transformation of fibroblasts. However, are these
mutants able to provide information about the mecha-
nism by which Ras acts to give a specific short-term
biological response? In the case of Ras induction of
membrane ruffling and lamellipodia, it has been shown
that activated Ras induces very strong ruffling through
a Rac-mediated pathway (Ridley et al., 1992). We have
shown here that activated PI 3-kinase also induces
membrane ruffling, again through a Rac-mediated
mechanism. The only Ras partial loss of function mutant
to cause ruffling is C40: this, together with the inability
of Raf or Ral to cause ruffling, rules out Raf and Ral.GDS
as effectors on the ruffling pathway. Since C40 Ras
stimulates PI 3-kinase and causes membrane ruffling in
an LY294002- and wortmannin-sensitive manner in PAE
cells, it is very likely that this mutant is causing ruffling
through interaction with a drug-sensitive PI 3-kinase.
In contrast to C40 Ras±induced ruffling, V12 Ras±
induced ruffling is not fully sensitive to PI 3-kinase inhibi-
tors in porcine aortic endothelial cells (Figure 6A) or
in Swiss 3T3 cells (C. D. Nobes and A. Hall, personal
communication). This has previously been interpreted
as evidence that Ras controls Rac-dependent ruffling
by a PI 3-kinase±independent mechanism. However, the
use of a different means of inhibiting PI 3-kinase func-
tion, expression of dominant-negative constructs basedFigure 7. Effect of LY294002 and p85 Overexpression on Ras-
on the p85 regulatory subunit, shows that the V12 Ras±Induced Cellular PIP3 Levels
induced ruffling is entirely sensitive to this form of dis-(A) PIP3 levels were measured in metabolically labeled, serum-
ruption of PI 3-kinase signaling. Other SH2 and SH3starved NIH 3T3 cells. Cells were treated with LY294002 for 90 min
before lysis. PDGF (50 ng/ml) treatment was for 3 min before lysis. domain±containing constructs, such as one derived
V12 Ras was expressed by retroviral infection for 48 hr before la- from p120GAP, are inactive. Since the Bcr domain of p85
beling. is not required for inhibition of Ras-induced ruffling, and
(B) V12 Ras and PI 3-kinase constructs, including wild-type p110,
p85 constructs do not inhibit Rac-induced ruffling, it iswere transfected into COS-7 cells. PIP3 levels were measured in
unlikely that direct interaction of p85 with GTP-boundwhole cells 48 hr after transfection.
Rac or Cdc42 is responsible for this inhibition (Zheng
et al., 1994). The exact mechanism by which overexpres-fact that v-Src uses several signaling pathways to trans-
sion of p85 mutants interferes with PI 3-kinase has notform cells, only some of which involve Ras. Src may be
beendefined, but is likely to involve titering out upstreamalso able to control PI 3-kinase in a Ras-independent
signaling molecules that are needed for activation of PImanner.
3-kinase both by receptor tyrosine kinases and by Ras.Looking further down the effector pathways, Raf can
As shown in Figure 7B, overexpression of p85 or Dp85synergize with Rac or Rho, as shown previously by oth-
does indeed inhibit the ability of V12 Ras to activate PIers (Khosravi-Far et al., 1995; Qiu et al., 1995a, 1995b),
3-kinase in whole cells, as determined by measuringand PI 3-kinase can synergize with Rho, but not with
PIP3 levels. Although Ras directly interacts with andRac. This suggests that Rac and PI 3-kinase lie on the
moderately activates p110 in vitro, it is likely that in ordersame pathway, most likely with PI 3-kinase acting up-
to achieve efficient activation of PI 3-kinase by V12 Rasstream of Rac (Hawkins et al., 1995), but that Rho lies
in whole cells, at least basal levels of other signals areon a different pathway; this ties in with the ability of
also required, including one mediated by p85. Endoge-Rac and Rho to synergize with each other in causing
nous p110 is likely to be effectively uncoupled fromtransformation. Placing Rac and Rho on different path-
stimulatory signals feeding into p85 by massive overex-ways differs from the model derived from actin cytoskel-
eton rearrangements in Swiss 3T3 cells in which Rac pression of this protein. Overexpression of Ras and of
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p85 have previously been shown to exert opposing influ- controls more than one pathway comes from a combina-
tion of genetic and two-hybrid analysis in yeast, particu-ences on mammalian PI 3-kinase activity in a model
system in S. pombe (Kodaki et al., 1994), suggesting larly in S. pombe, where Ras control of Byr2 and Scd1
is well established. The data presented here indicatethat in the absence of upstream positive signals, p85
has a negative influence on the enzymatic activity of that activated Ras is capable of performing multiple
roles in mammalian cells. Activation of both the Raf andp110 within a cellular context. It cannot be ruled out
that a function of PI 3-kinase, in addition to its lipid PI 3-kinase pathways are needed for efficient transfor-
mation by Ras oncogenes, while activated Ras-inducedkinase activity, is important in Ras-induced membrane
ruffling. cortical actin rearrangement operates through a PI
3-kinase, and not a Raf or Ral.GDS, pathway.The fact that V12 Ras±induced ruffling is sensitive
to mutant p85 overexpression but not to LY294002 or
wortmannin treatment suggests that Ras could activate Experimental Procedures
an isoform of PI 3-kinase that is profoundly resistant to
Plasmids and Proteinsthese inhibitors: it is already clear that Ras will interact
The V12 mutant H-ras cDNA was cloned into the pcDNA3 vector,with at least four different PI 3-kinase family members
and point mutations were carried out using the In Vitro Mutagenesis
(P. R. V., P. H. W., M. D. W., and J. D., unpublished Kit (Pharmacia). For bacterial expression, a BamH1 site was added
data), although none of these are known to be resistant in-frame to the second codon by PCR and the inserts cloned into
to these drugs. Measurement of PIP3 levels in V12 Ras the pGEX (Pharmacia) andpRSET (Invitrogen) vectors for expression
as GST- and histidine-tagged fusion proteins, respectively. To haveexpressing NIH 3T3 cells shows that the Ras-induced,
the effector mutants on a G12 background for GAP assays, the V12but not PDGF-induced, elevation of this lipid is partially
mutation was mutated back to G12 by PCR and the inserts clonedresistant to treatment of cells with LY294002 (Figure 7).
into the pRSET vector. Fusion proteins were purified according to
A novel C2 domain containing PI 3-kinase isoform has the manufacturer's protocols. The p110K227E mutant has been de-
recently been reported that is about fifty times less sen- scribed elsewhere (Rodriguez-Viciana et al., 1996). p85awt, p85
sitive than p110a to wortmannin (Virbasius et al. 1996). DiSH2-N (deletion of amino acids 478±513), p85 DiSH2-C (deletion
of amino acids 494±590), and p85Dbcr (deletion of amino acidsSince many growth factors rapidly induce both PI
134±302) were subcloned into the EcoR1 site of pSG5. Full-length3-kinase inhibitor±sensitive membrane ruffling and Ras
Ral.GDS expression construct was a gift from Robert Weinberg;activation, it is possible that Ras function is required for
Ral.GDS fusion protein, from Johannes Bos; the N-terminal (residues
the growth factor receptors to induce PI 3-kinase activity 1±666) p120GAP SH2/SH3 construct, from Channing Der; the domi-
and, hence, to cause actin rearrangement. Indeed, it nant-negative MEK construct (A221), from Chris Marshall; and the
has been recently reported that in NIH 3T3 cells, Ras dominant-negative Rac (N17 rac), from Alan Hall. Retroviruses were
generated by cloning inserts into the pLXSN vector and transfectingfunction is required for efficient activation of PI 3-kinase
them into the GP1E 86 packaging cell line. Pools of G418-resistantin response to PDGF (Klinghofer et al., 1996). In the
colonies were selected and, when confluent, the medium was col-case of Swiss 3T3 cells, PDGF-induced ruffling does not
lected and frozen as aliquots in the presence of polybrene.
appear to be inhibited by neutralizing Ras antibodies
(Ridley et al., 1992); however, in MDCK cells, hepatocyte Ras/Effector In Vitro Binding Assay
growth factor±induced ruffling is entirely sensitive to Ras-binding assays were carried out as described in Warne et al.
these Ras antibodies (Ridley et al., 1995). In both cases, (1993) and Rodriguez-Viciana et al. (1994). Ras (0.5 mM) and effector-
GST (0.5 mg) were used in a 200 ml assay. Scintillation ProximityRac function is required for ruffling to occur. We have
Assay was performed as described in Skinner et al. (1994).found that the ability of anti-Ras antibodies or N17 Ras
to inhibit ruffling varies greatly with cell type and the
Measurement of Raf and PI 3-Kinase Activitynature of the external stimulus. It is clear that there are
in COS-7 Cells
multiple pathways leading to PI 3-kinase activation: in Constructs were electroporated into COS-7 cells as described pre-
some cases, Ras is necessary; in other cases, it is not. viously (Rodriguez-Viciana et al., 1994). After 48 hr, PI 3-kinase
A very similar situation has been described for growth activity was assayed in the absence of serum by measuring 39 phos-
phorylated phosphoinositide lipids, as described by Carter andfactor induction of ERK2 MAP kinase in fibroblasts, in
Downes (1992). Raf activity was assayed in the absence of serum bywhich Ras is required for PDGF- and insulin-induced,
cotransfecting a Myc-tagged c-Raf-1 construct and by performing abut not EGF-induced, activation in Rat-1 and NIH 3T3
coupled MEK/ERK2 kinase assay on 9E10 immunoprecipitates as
fibroblasts, but both PDGF- and EGF-induced ERK2 ac- described by Leevers and Marshall (1992). For lipid analysis in NIH
tivation is insensitive to inhibition of Ras in Swiss 3T3 3T3 cells, Ras retrovirus±containing supernatant was added to sub-
fibroblasts, while insulin requires Ras function (Burger- confluent NIH 3T3 cells and replaced 4 hr later with fresh medium.
After 24 hr incubation to to allow expression of Ras protein, theing et al., 1993). The fact that PDGF-induced ruffling in
cells were labeled for 16 hr with 32P-orthophosphate in phosphate-PAE cells does not show a significant degree of resis-
free medium containing 0.2% dialysed calf serum, and PIP3 levelstance to LY294002 suggests that the contribution of
were measured by the same method as described above for COS
endogenous Ras to PDGF-induced PI 3-kinase activa- cells.
tion is relatively small in this case, at least assuming that
endogenous Ras interacts with the same PI 3-kinase Transformation Assays in NIH 3T3 Cells
isoforms as does V12 Ras. For the data in Figures 3 and 4, low passage NIH 3T3 cells were
seeded at 1.25 3 105 cells per well in 6-well dishes the day beforeThe possibility that endogenous Ras normally acti-
lipofection with 1.5 mg of each plasmid, apart from V12 Ras plasmid,vates multiple effector pathways is supported by the
in which 20 ng was used, using the Tfx-50 reagent (Promega) ac-observation that, in a number of mammalian systems,
cording to the manufacturer's protocols. Two days later, the cells
Ras function is required for growth factor activation of were transferred to 10 cm plates. After reaching confluence, they
PI 3-kinase (Rodriguez-Viciana et al., 1994; Klinghofer were kept for two weeks in DME medium containing 5% calf serum,
et al., 1996) as well as Raf (Marshall, 1996). Probably after which they were stained with 0.5% crystal violet. For study of
inhibitory effects on transformation, 40 ng of V12 Ras or 20 ngthe most compelling evidence to date that Ras normally
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v-Src plasmid was cotransfected with 2 mg of inhibitory construct. and Stephens, L. (1995). PDGF stimulates an increase in GTP-rac
via activation of phosphoinositide 3-kinase. Curr. Biol. 5, 393±403.Quantitation plotted is the means and standard errors of duplicate
assays and is representative of at least three experiments. For the Joneson, T., White, M.A., Wigler, M.H., and Bar-Sagi, D. (1996).
data in Table 1, stably transformed NIH 3T3 cells expressing low Stimulation of membrane ruffling and MAP kinase activation by dis-
(Clone 1, about equal level of V12 Ras to endogenous Ras) or high tinct effectors of Ras. Science 271, 810±812.
levels (Clone 2, about 8-fold more V12 Ras than endogenous Ras)
Khosravi-Far, R., Solski, P.A., Clark, G.J., Kinch, M.S., and Der, C.J.
of V12 Ras with a puromycin resistance marker were infected with
(1995). Activation of Rac1, RhoA, and mitogen-activated protein
retroviruses expressing p85a, p85b, or Dp85a (p85 DiSH2-N) with
kinases is required for Ras transformation. Mol. Cell. Biol. 15, 6443±
a neo resistance marker. Cells were selected with G418 for 5 days,
6453.
during which time all control uninfected cells died, then soft agar
Khosravi-Far, R., White, M.A., Westwick, J.K., Solski, P.A., Chrza-colony formation assays were set up with 1000 cells in the presence
nowska-Wodnicka, M., Van Aelst, L., Wigler, M.H., and Der, C.J.of G418. Colonies visible by the naked eye were scored in duplicates
(1996). Oncogenic Ras activation of Raf/MAP kinase independentat 3 weeks.
pathways is sufficient to cause tumorigenic transformation. Mol.
Cell. Biol. 16, 3923±3933.
Microinjections and Immunofluorescence
Klinghofer, R.A., Duckworth, B., Valius, M., Cantley, L., and Kaz-Porcine aortic endothelial 1 3 104 cells were seeded in 13 mm glass
lauskas, A. (1996). PDGF-dependent activation of PI3 kinase is regu-coverslips two days before and serum starved overnight in 0.5%
lated by receptor binding of SH2 domain±containing proteins whichfetal calf serum before injections. When injecting proteins, V12 Rac,
influence Ras activity. Mol. Cell. Biol. 16, 5905±5914.V12 Cdc42, N17 Rac, and N17 Cdc42 were expressed as GST-fusion
proteins, purified, and cleaved as described in Self and Hall (1995). Kodaki, T., Woscholski, R., Hallberg, B., Rodriguez-Viciana, P.,
V12 Ras proteins expressed either as GST- or as histidine-tagged Downward, J., and Parker, P.J. (1994). The activation of phosphati-
fusion proteins were found to have very poor biological activity; the dylinositol 3-kinase by Ras. Curr. Biol. 4, 798±806.
V12 Ras protein used for microinjection experiments was purified Kotani, K., Yonezawa, K., Hara, K., Ueda, H., Kitamura, Y., Sakaue,
from the soluble fraction of Sf-9 cells infected with a V12 Ras bacu- H., Ando, A., Chavaneau, A., Calas, B., Grigorescu, F., et al. (1994).
lovirus. When microinjecting DNA, plasmids were injected into the Involvementof phosphoinositide 3-kinase in insulin or IGF-1 induced
nucleus at a concentration of 100 mg/ml, and the cells fixed after 5 membrane ruffling. EMBO J. 13, 2313±2321.
hr. Guinea pig IgG at 2 mg/ml was coinjected in all cases to help
Leevers, S.J., and Marshall, C.J. (1992). Activation of extracellularidentify injected cells. LY294002 was used at 20 mM. An Eppendorf
signal±regulated kinase ERK2 by p21ras oncoprotein. EMBO J. 11,
microinjector (Model No. 5242) and micromanipulator (Model No.
569±574.
5170) were used. Cells were fixed, and immunofluorescence was
Marshall, C.J. (1996). Ras effectors. Curr. Opin. Cell Biol. 8, 197±204.carried out as described in Ridley (1995). All micrographs shown
are representative examples of microinjected cells from at least four McCarthy, S.A., Samuels, M.L., Pritchard, C.A., Abraham, J.A., and
similar experiments. McMahon, M. (1995). Rapid induction of heparin-binding epidermal
growth factor/diphtheria toxin receptor expression by Raf and Ras
oncogenes. Genes Dev. 9, 1953±1964.Acknowledgments
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